Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F in Healthy Postmenopausal Women
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2015
Price : $35 *
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Breast cancer; Multiple myeloma
- Focus Pharmacokinetics
- 25 Mar 2015 Status changed from recruiting to completed, according to to ClinicalTrials.gov record.
- 03 Dec 2013 Planned End Date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 03 Dec 2013 Planned number of patients changed from 35 to 63 as reported by ClinicalTrials.gov.